Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Baqiyatallah Research Center for Gastroenterology and Liver Diseases (BRCGL), Clinical Sciences Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Helicobacter. 2024 Mar-Apr;29(2):e13067. doi: 10.1111/hel.13067.
Helicobacter pylori (H. pylori) is a rod-shaped, gram-negative, microaerophilic bacterium that can be identified by gram staining. Its relationship with cancer is significant since it is involved in approximately 80% of gastric cancers and 5.5% of all malignant cancers. Two lines of treatment have been defined for H. pylori, but almost 40% of patients do not respond to the first line. Recent trials have investigated oral Immunotherapy as a new treatment method. The aim of this systematic review was to investigate the potential effects of oral Immunotherapy on eradication rate of H. pylori in human studies.
The systematic review was performed according to PRISMA guidelines. We searched online databases, including Scopus, PubMed, and Web of Science (ISI). Our search strategy was limited to English articles and studies on human populations that use oral immunotherapy for H. pylori.
The total number of primary research records in different databases was 2775. After removing duplicate articles (n = 870), we excluded 1829 for reasons including non-human studies, irrelevance to our study objective, non-English language, or lack of information. Of the remaining 76 articles, only seven had sufficient information, and the rest were excluded. The studies were divided into two groups: those that used bovine antibody and those that used immunoglobulin Y to eradicate H. pylori.
In the group of Immunoglobulin Y, three out of four studies suggest that using Immunoglobulin Y for the treatment of H. pylori infection is significant. However, the group using bovine antibody for the treatment of H. pylori infection has various results, as two out of three studies concluded that bovine antibody therapy is not significant.
幽门螺杆菌（H. pylori）是一种杆状、革兰阴性、微需氧细菌，可通过革兰氏染色进行鉴定。它与癌症的关系非常重要，因为它与大约 80%的胃癌和 5.5%的所有恶性肿瘤有关。已经确定了两种针对 H. pylori 的治疗方法，但近 40%的患者对一线治疗没有反应。最近的试验已经研究了口服免疫疗法作为一种新的治疗方法。本系统评价的目的是研究口服免疫疗法对人类研究中 H. pylori 根除率的潜在影响。
系统评价按照 PRISMA 指南进行。我们搜索了在线数据库，包括 Scopus、PubMed 和 Web of Science（ISI）。我们的搜索策略仅限于英文文章和针对使用口服免疫疗法治疗 H. pylori 的人类人群的研究。
不同数据库中初级研究记录的总数为 2775 条。在去除重复文章（n=870）后，我们排除了 1829 篇文章，原因包括非人类研究、与我们的研究目标无关、非英语语言或缺乏信息。在剩下的 76 篇文章中，只有 7 篇有足够的信息，其余的都被排除了。这些研究分为两组：一组使用牛抗体，另一组使用免疫球蛋白 Y 来根除 H. pylori。
在使用免疫球蛋白 Y 的组中，四项研究中有三项表明使用免疫球蛋白 Y 治疗 H. pylori 感染是有效的。然而，使用牛抗体治疗 H. pylori 感染的组有不同的结果，因为三项研究中有两项得出结论，牛抗体治疗并不显著。
